Jackson Square Capital LLC Buys New Stake in Astrazeneca Plc $AZN

Jackson Square Capital LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 38,184 shares of the company’s stock, valued at approximately $6,224,000. Astrazeneca comprises 0.9% of Jackson Square Capital LLC’s investment portfolio, making the stock its 29th biggest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. Triumph Capital Management increased its holdings in Astrazeneca by 32.6% during the 3rd quarter. Triumph Capital Management now owns 252 shares of the company’s stock valued at $41,000 after purchasing an additional 62 shares during the period. Riversedge Advisors LLC raised its position in Astrazeneca by 2.9% during the 3rd quarter. Riversedge Advisors LLC now owns 2,347 shares of the company’s stock valued at $379,000 after purchasing an additional 67 shares during the last quarter. Veery Capital LLC raised its position in Astrazeneca by 3.9% during the 3rd quarter. Veery Capital LLC now owns 1,857 shares of the company’s stock valued at $300,000 after purchasing an additional 70 shares during the last quarter. Signal Advisors Wealth LLC lifted its holdings in Astrazeneca by 2.7% in the 3rd quarter. Signal Advisors Wealth LLC now owns 2,778 shares of the company’s stock worth $448,000 after buying an additional 72 shares during the period. Finally, Rosenberg Matthew Hamilton lifted its holdings in Astrazeneca by 3.8% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 2,129 shares of the company’s stock worth $344,000 after buying an additional 78 shares during the period. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Down 0.2%

Shares of AZN stock traded down $0.32 during midday trading on Monday, reaching $165.09. 991,449 shares of the stock were exchanged, compared to its average volume of 2,805,244. Astrazeneca Plc has a 1 year low of $153.41 and a 1 year high of $212.71. The company’s 50 day moving average is $162.16 and its two-hundred day moving average is $175.96. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47. The firm has a market cap of $256.03 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 1.40 and a beta of 0.27.

Astrazeneca (NYSE:AZN) last announced its earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.13. The firm had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%. The business’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.17 EPS. On average, equities research analysts predict that Astrazeneca Plc will post 9.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AZN. Zacks Research upgraded Astrazeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Deutsche Bank Aktiengesellschaft upgraded Astrazeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Royal Bank Of Canada assumed coverage on Astrazeneca in a report on Tuesday, September 8th. They set an “outperform” rating for the company. CICC Research started coverage on Astrazeneca in a research note on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target for the company. Finally, Citigroup reiterated a “buy” rating on shares of Astrazeneca in a report on Tuesday, October 6th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $206.67.

Astrazeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.